HBL – Hadasit Bio-Holdings Ltd.
May 5, 2015
Securities Authority Tel Aviv Stock Exchange Ltd.
Re: Allowance of Patent in Australia - ProtAb Ltd
The Company is pleased to announce that ProtAb Ltd, a portfolio company (hereinafter: "ProtAb"), received allowance of a patent in Australia titled:
Humanized Antibodies Specific for Hsp65-Derived Peptide-6 Methods and Uses Thereof(Australian Patent Application No. 2010290844) (hereinafter: the “Patent”).
The patent covers humanized antibodies including lead product candidate Prozumab, as well as the use of Prozumab and other humanized antibodies to treat arthritis and inflammatory bowel disease.
The Company has patent applications under review in a number of other countries, and has been approved already in the U.S. and China.
The Patent term is until September, 2030.
The company holds 69.54% of the share capital of ProtAb, which is focused on the development of novel therapeutic agents for the treatment of Inflammatory Bowel Diseases (including Crohn’s disease and Ulcerative Colitis) and additional autoimmune diseases.